4534
Mochida Pharmaceutical Co.,Ltd.
持田製薬
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
110,179
Mar 2023
103,261
Mar 2024
102,885
Mar 2025
105,159
Mar 2026
116,951
Operating profit(million JPY)
Mar 2022
14,392
Mar 2023
8,507
Mar 2024
5,802
Mar 2025
8,126
Mar 2026
10,147
Operating profit margin(%)
Mar 2022
13.06
Mar 2023
8.24
Mar 2024
5.64
Mar 2025
7.73
Mar 2026
8.68
Profit before tax(million JPY)
Mar 2022
14,591
Mar 2023
9,044
Mar 2024
6,160
Mar 2025
8,052
Mar 2026
11,171
Profit(million JPY)
Mar 2022
10,569
Mar 2023
6,649
Mar 2024
4,547
Mar 2025
5,685
Mar 2026
7,903
Total assets(million JPY)
Mar 2022
163,139
Mar 2023
158,831
Mar 2024
158,800
Mar 2025
160,121
Mar 2026
182,720
Cash and cash equivalents(million JPY)
Mar 2022
40,515
Mar 2023
38,010
Mar 2024
24,290
Mar 2025
48,151
Mar 2026
31,058
Cash flows from operating activities(million JPY)
Mar 2022
7,459
Mar 2023
7,297
Mar 2024
-7,480
Mar 2025
9,354
Mar 2026
-7,350
Cash flows from investing activities(million JPY)
Mar 2022
-2,007
Mar 2023
-2,949
Mar 2024
74
Mar 2025
17,355
Mar 2026
-16,848
Cash flows from financing activities(million JPY)
Mar 2022
-5,956
Mar 2023
-6,884
Mar 2024
-6,393
Mar 2025
-2,865
Mar 2026
7,033
Return on equity(%)
Mar 2022
8.3
Mar 2023
5.2
Mar 2024
3.6
Mar 2025
4.4
Mar 2026
5.8
Equity ratio(%)
Mar 2022
78.9
Mar 2023
79.8
Mar 2024
80.6
Mar 2025
81.6
Mar 2026
76.8
Earnings per share(JPY per share)
Mar 2022
277.39
Mar 2023
178.93
Mar 2024
126.8
Mar 2025
160.36
Mar 2026
222.96
Net assets per share(JPY per share)
Mar 2022
3,424.21
Mar 2023
3,470.18
Mar 2024
3,609.64
Mar 2025
3,686.69
Mar 2026
3,958.46
Dividend per share(JPY per share)
Mar 2022
90
Mar 2023
80
Mar 2024
80
Mar 2025
80
Mar 2026
80
Payout ratio(%)
Mar 2022
32.45
Mar 2023
44.71
Mar 2024
63.09
Mar 2025
49.89
Mar 2026
35.88
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.